State Street
MIRM icon

State Street’s Mirum Pharmaceuticals MIRM Stock Holding History

State Street’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254M Buy
2,170,689
+226,408
+12% +$22.7M 0.01% 905
2026
Q1 		$180M Sell
1,944,281
-199,711
-9% -$18.8M 0.01% 1000
2025
Q4 		$169M Buy
2,143,992
+797,088
+59% +$57.2M 0.01% 1040
2025
Q3 		$98.7M Sell
1,346,904
-28,724
-2% -$1.83M ﹤0.01% 1337
2025
Q2 		$70M Sell
1,375,628
-118,938
-8% -$5.3M ﹤0.01% 1499
2025
Q1 		$67.3M Buy
1,494,566
+112,939
+8% +$5.32M ﹤0.01% 1493
2024
Q4 		$57.1M Sell
1,381,627
-412,101
-23% -$17.2M ﹤0.01% 1649
2024
Q3 		$70M Buy
1,793,728
+297,511
+20% +$11.9M ﹤0.01% 1532
2024
Q2 		$51.2M Sell
1,496,217
-1,326,255
-47% -$34.8M ﹤0.01% 1667
2024
Q1 		$70.9M Buy
2,822,472
+1,087,697
+63% +$29.9M ﹤0.01% 1528
2023
Q4 		$51.2M Buy
1,734,775
+113,865
+7% +$3.45M ﹤0.01% 1695
2023
Q3 		$51.2M Buy
1,620,910
+126,493
+8% +$3.46M ﹤0.01% 1607
2023
Q2 		$38.7M Buy
1,494,417
+323,992
+28% +$8.62M ﹤0.01% 1823
2023
Q1 		$28.1M Sell
1,170,425
-588,193
-33% -$13.4M ﹤0.01% 2000
2022
Q4 		$34.3M Buy
1,758,618
+769,656
+78% +$15.2M ﹤0.01% 1885
2022
Q3 		$20.8M Buy
988,962
+713,095
+258% +$17.2M ﹤0.01% 2193
2022
Q2 		$5.37M Buy
275,867
+143,123
+108% +$3.38M ﹤0.01% 3068
2022
Q1 		$2.92M Buy
132,744
+9,009
+7% +$184K ﹤0.01% 3424
2021
Q4 		$1.97M Sell
123,735
-3,354
-3% -$52.2K ﹤0.01% 3637
2021
Q3 		$2.53M Buy
127,089
+1,303
+1% +$21.2K ﹤0.01% 3549
2021
Q2 		$2.17M Buy
125,786
+35,168
+39% +$630K ﹤0.01% 3533
2021
Q1 		$1.8M Sell
90,618
-4,400
-5% -$84.2K ﹤0.01% 3478
2020
Q4 		$1.66M Sell
95,018
-7,785
-8% -$153K ﹤0.01% 3429
2020
Q3 		$1.98M Buy
102,803
+7,148
+7% +$153K ﹤0.01% 3202
2020
Q2 		$1.86M Buy
95,655
+45,427
+90% +$759K ﹤0.01% 3203
2020
Q1 		$703K Buy
50,228
+27,409
+120% +$450K ﹤0.01% 3377
2019
Q4 		$560K Buy
22,819
+3,203
+16% +$34.1K ﹤0.01% 3504
2019
Q3 		$197K Buy
+19,616
New +$241K ﹤0.01% 3613

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street's MIRM Position: Q2 2026 in Review

State Street increased its Mirum Pharmaceuticals (MIRM) stake by 12% in Q2 2026, buying an estimated $22.7M and bringing the position to 2,170,689 shares worth $254M. The position accounts for 0.01% of the portfolio, ranked #905.

State Street first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • State Street held 2,170,689 shares of Mirum Pharmaceuticals worth $254M as of Q2 2026.
  • State Street bought 226,408 Mirum Pharmaceuticals shares in Q2 2026, an estimated $22.7M.
  • Mirum Pharmaceuticals made up 0.01% of State Street's portfolio in Q2 2026, its #905 holding.
  • State Street first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.